AGCT develops a groundbreaking PCR-based assay technology that will…
What we do
Revolutionize
non-invasive liquid biopsy testing
Help save lives
by detecting cancer earlier
Benefit patients
through earlier and faster decision-making in treatment selection
Be usable
in any molecular diagnostic laboratory
Non-invasive liquid biopsy tests are aimed at fundamentally changing cancer diagnostics and treatment. Existing technologies have performance limitations and narrow the potentials of liquid biopsy. AGCT’s disruptive technology introduces molecular assays with unmatched sensitivity and specificity in cancer detection. At the same time our technology can be applied on standard laboratory equipment. The future of new cancer diagnostics, accessible to everyone, can start today.
Our Technology
AGCT’s cyberPCR technology creates a new dimension of sensitivity and specificity in cancer detection…
Unmatched performance
Highest discrimination of mutant vs wild-type DNA molecules
Feedback digital control
Exclusion PCR amplifies the mutant target sequence only in each cycle
Easy to use
Can be run in any MDx laboratory using existing PCR equipment
Universal
Technology will be developed across MDx platforms
AGCT‘s proprietary cyberPCR already discriminates at the amplification step. Only mutant target sequences are amplified, permitting an unprecedented signal-noise ratio and a revolutionary level of rare mutant molecule detection for liquid biopsy.
PCR
Low signal-to-noise ratio
- PCR, CAST, dPCR, NGS amplify wild-type and mutated DNA
- Discrimination necessary at the detection step
AGCT's cyberPCR
High signal-to-noise ratio
- cyberPCR only amplifies mutated DNA sequence
- Discrimination already at the amplification step, leading to high level of specimen detection